Home>Topics>Stocks>Onyx Pharmaceuticals

Onyx Pharmaceuticals ONXX

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Headlines
    1. Amgen cancer drug fails Phase 3 trial

      Headlines

      Wed, 13 Aug 2014

      dexamethasone (or equivalent corticosteroids) plus optional cyclophosphamide. Despite the setback, Amgen subsidiary Onyx Pharmaceuticals ( ONXX ) President Pablo J. Cagnoni says, "While it is unfortunate that the FOCUS study did not meet its primary

    2. Aspire Data A Big Plus For Amgen And Celgene

      Headlines

      Tue, 5 Aug 2014

      blossoming oncology space. It picked up the proteasome inhibitor just under a year ago, along with the rest of Onyx Pharmaceuticals , for about $9.5 billion. While second quarter sales reached a healthy $78 million, it's still Complete

    3. Biotech IPOs: What to Learn from a Banner Year

      Headlines

      Thu, 23 Jan 2014

      huge sums for smaller innovators. For example, last summer, Amgen upped its offer to buy cancer drug maker Onyx Pharmaceuticals from $9.3 billion to $9.7 billion. Such deals — along with generally healthy balance sheets and access to capital among life sciences companies

    4. ClearBridge Fund Prepared for Extended Rally

      Video Reports

      Fri, 11 Oct 2013

      sclerosis compound. [TICKER:AMGN] Amgen as well, which recently announced an acquisition of [TICKER:VRTX] Onyx Pharmaceuticals , has been strong from an earnings perspective and a stock perspective. And a name like Vertex, which has been

      Onyx Pharmaceuticals found at 1:09

      multiple sclerosis compound. [TICKER:AMGN] Amgen as well, which recently announced an acquisition of [TICKER:VRTX] Onyx Pharmaceuticals , has been strong from an earnings perspective and a stock perspective. And a name like Vertex, which has been a company that
    5. Our Outlook for the Credit Markets

      Headlines

      Wed, 25 Sep 2013

      with its internal prospects last quarter when it decided to make the $10 billion debt-funded acquisition of Onyx Pharmaceuticals ONXX (rating: SUS, no moat). This acquisition will boost Amgen's top-line growth by nearly 200 basis points

    6. Onyx deal expected to give Amgen a big boost

      Headlines

      Mon, 26 Aug 2013

      Aug 26 (Reuters) - Investors reacted favorably on Monday to Amgen Inc's $10.4 billion purchase of Onyx Pharmaceuticals Inc, which gives the world's largest biotech company full rights to a blood...

    7. Reasonably Priced Onyx Acquisition Is Positive Strategic Move for Amgen; Maintain Wide Moat Rating

      Commentary

      Mon, 26 Aug 2013

      After several weeks of media speculation, Amgen finally announced the acquisition of Onyx Pharmaceuticals for $125 per share, valuing the company at $10.4 billion (or $9.7 billion net of cash). As we stated previously, we

    8. Amgen seeks drug trial data before finalizing Onyx deal: sources

      Headlines

      Thu, 15 Aug 2013

      NEW YORK (Reuters) - Amgen Inc, the drugmaker in advanced discussions to buy Onyx Pharmaceuticals Inc, has asked Onyx for some of the data from an ongoing trial on the company's new blood cancer...

    9. Deals of the day -- mergers and acquisitions

      Headlines

      Wed, 7 Aug 2013

      (Adds Onyx Pharmaceuticals , Telediffusion de France, TPG Capital and others)

    10. New Morningstar Analyst Report for Onyx Pharmaceuticals Inc.

      Stock Reports

      Mon, 15 Jul 2013

      to see clearer guidelines for measuring performance. Onyx Pharmaceuticals develops and markets novel therapies that target molecular ..... into non-small-cell lung cancer and melanoma). Onyx Pharmaceuticals , with its promising small-molecule drug Nexavar

    « Prev12345Next »
    Content Partners